Cinctive Capital Management LP Acquires New Position in ICU Medical, Inc. $ICUI

Cinctive Capital Management LP acquired a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 5,779 shares of the medical instruments supplier’s stock, valued at approximately $693,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ICUI. SJS Investment Consulting Inc. increased its stake in shares of ICU Medical by 41,000.0% in the third quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 410 shares in the last quarter. Covestor Ltd lifted its stake in shares of ICU Medical by 70.7% during the 3rd quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock valued at $68,000 after buying an additional 236 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after buying an additional 101 shares in the last quarter. Headlands Technologies LLC bought a new position in ICU Medical in the 2nd quarter worth approximately $177,000. Finally, United Services Automobile Association purchased a new position in ICU Medical in the 1st quarter valued at approximately $218,000. Institutional investors own 96.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. Piper Sandler raised their price target on ICU Medical from $172.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Sunday, February 15th. Finally, KeyCorp boosted their price objective on ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $179.33.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $126.96 on Tuesday. The company has a 50 day moving average of $147.64 and a 200 day moving average of $138.16. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60. The stock has a market cap of $3.13 billion, a P/E ratio of 6,351.18, a P/E/G ratio of 1.82 and a beta of 0.79. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $160.29.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The business had revenue of $535.94 million for the quarter, compared to analysts’ expectations of $541.20 million. During the same period in the prior year, the company posted $2.11 EPS. The business’s revenue for the quarter was down 14.1% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.